Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. LYRA
stocks logo

LYRA

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
440.00K
+110.53%
-3.757
-53.03%
0.00
-100%
-1.360
-79.08%
0.00
-100%
-1.540
-72.05%
Estimates Revision
The market is revising No Change the revenue expectations for Lyra Therapeutics, Inc. (LYRA) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -34.31%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Down
down Image
-34.31%
In Past 3 Month
Wall Street analysts forecast LYRA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LYRA is 16.00 USD with a low forecast of 16.00 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
Wall Street analysts forecast LYRA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LYRA is 16.00 USD with a low forecast of 16.00 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Buy
3 Hold
0 Sell
Hold
Current: 4.500
sliders
Low
16.00
Averages
16.00
High
16.00
Current: 4.500
sliders
Low
16.00
Averages
16.00
High
16.00
H.C. Wainwright
Neutral
upgrade
$2 -> $16
2025-06-10
Reason
H.C. Wainwright
Price Target
$2 -> $16
2025-06-10
upgrade
Neutral
Reason
H.C. Wainwright raised the firm's price target on Lyra Therapeutics to $16 from $2 and keeps a Neutral rating on the shares following the company's reverse stock split.
HC Wainwright & Co.
Matthew Caufield
Hold
Reiterates
$2
2025-03-14
Reason
HC Wainwright & Co.
Matthew Caufield
Price Target
$2
2025-03-14
Reiterates
Hold
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Lyra Therapeutics Inc (LYRA.O) is -0.54, compared to its 5-year average forward P/E of -2.14. For a more detailed relative valuation and DCF analysis to assess Lyra Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-2.14
Current PE
-0.54
Overvalued PE
-0.77
Undervalued PE
-3.51

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-0.95
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.35
Undervalued EV/EBITDA
-2.26

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
85.42
Current PS
0.00
Overvalued PS
173.36
Undervalued PS
-2.52
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders areSelling! The selling amount has increased 2528.68% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areSelling! The selling amount has increased 2528.68% over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

LYRA News & Events

Events Timeline

(ET)
2025-11-12
16:15:40
Lyra Therapeutics announces Q3 EPS of $3.38, below consensus estimate of $4.07
select
2025-08-12 (ET)
2025-08-12
16:13:48
Lyra Therapeutics reports Q2 EPS ($5.51), consensus ($4.78)
select
2025-06-02 (ET)
2025-06-02
07:13:10
Lyra Therapeutics says ENLIGHTEN 2 trial of LYR-210 met primary endpoint
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.5
11-11NASDAQ.COM
Assertio (ASRT) Exceeds Q3 Earnings and Revenue Projections

  • Earnings Performance: Assertio (ASRT) reported quarterly earnings of $0.11 per share, exceeding expectations of a loss of $0.08 per share, marking a significant earnings surprise of +237.50%.

  • Revenue Growth: The company generated revenues of $49.46 million for the quarter, surpassing the Zacks Consensus Estimate by 83.86% and showing a year-over-year increase from $29.2 million.

  • Stock Outlook: Assertio shares have declined by 12.7% year-to-date, underperforming the S&P 500, and currently hold a Zacks Rank #3 (Hold), indicating expected performance in line with the market.

  • Industry Context: The Medical - Drugs industry, to which Assertio belongs, ranks in the top 37% of Zacks industries, suggesting that industry performance could significantly influence Assertio's stock movement in the future.

[object Object]
Preview
9.0
09-03Benzinga
Upstream's Innovative Sinus Treatment Reduces Surgical Requirements, Initial Trial Reveals

  • New Treatment Advances: Upstream Bio's Phase 2 VIBRANT trial for verekitug in chronic rhinosinusitis with nasal polyps showed significant reductions in nasal polyp and congestion scores, with a favorable safety profile and reduced need for surgery or corticosteroids.

  • Regulatory Developments: The FDA is reviewing GSK's marketing application for depemokimab for chronic rhinosinusitis, while Lyra Therapeutics reported positive results from its Phase 3 trial of LYR-210, indicating effective symptom improvement in patients without nasal polyps.

[object Object]
Preview
9.5
08-13NASDAQ.COM
Lyra Therapeutics Posts 85% Q2 Loss Drop

  • Financial Performance: Lyra Therapeutics reported a GAAP EPS loss of $5.51 for Q2 2025, which was less negative than expected, but its revenue of $0.18 million fell short of estimates and decreased significantly from the previous year. The company achieved cost reductions leading to a lower net loss compared to Q2 2024.

  • Clinical and Regulatory Developments: Positive results from the ENLIGHTEN 2 clinical trial for LYR-210 position the company favorably for future regulatory meetings, although no specific timeline for submission has been provided. The company is preparing for a Type C meeting with the FDA to discuss New Drug Application requirements while continuing to manage costs effectively.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Lyra Therapeutics Inc (LYRA) stock price today?

The current price of LYRA is 4.5 USD — it has increased 7.4 % in the last trading day.

arrow icon

What is Lyra Therapeutics Inc (LYRA)'s business?

Lyra Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on the development and commercialization of therapies for the localized treatment of patients with chronic rhinosinusitis (CRS). The Company is developing therapies for CRS, a prevalent inflammatory disease of the paranasal sinuses that leads to debilitating symptoms and significant morbidities. LYR-210, the Company’s lead product, is a bioabsorbable nasal implant designed to be administered in a simple, in-office procedure and is intended to deliver six months of continuous anti-inflammatory drug therapy to the sinonasal passages for the treatment of CRS with a single administration. LYR-210, being evaluated in the ENLIGHTEN Phase III clinical program, is intended for patients with and without nasal polyps. The drug embedded within LYR-210 is mometasone furoate (MF).

arrow icon

What is the price predicton of LYRA Stock?

Wall Street analysts forecast LYRA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LYRA is 16.00 USD with a low forecast of 16.00 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Lyra Therapeutics Inc (LYRA)'s revenue for the last quarter?

Lyra Therapeutics Inc revenue for the last quarter amounts to 25.00K USD, decreased -87.18 % YoY.

arrow icon

What is Lyra Therapeutics Inc (LYRA)'s earnings per share (EPS) for the last quarter?

Lyra Therapeutics Inc. EPS for the last quarter amounts to -3.38 USD, decreased -62.73 % YoY.

arrow icon

What changes have occurred in the market's expectations for Lyra Therapeutics Inc (LYRA)'s fundamentals?

The market is revising No Change the revenue expectations for Lyra Therapeutics, Inc. (LYRA) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -34.31%.
arrow icon

How many employees does Lyra Therapeutics Inc (LYRA). have?

Lyra Therapeutics Inc (LYRA) has 30 emplpoyees as of December 05 2025.

arrow icon

What is Lyra Therapeutics Inc (LYRA) market cap?

Today LYRA has the market capitalization of 7.94M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free